• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nu Skin Enterprises Reports First Quarter Results

    5/7/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care
    Get the next $NUS alert in real time by email

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue results within its guidance range.

    Executive Summary

    Q1 2026 vs. Prior-year Quarter

    Revenue

    $320.6 million; (12.0)%

      • +1.1% FX impact or $3.9 million

    Earnings Per Share (EPS)

    $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges

    Customers

    669,535; (14)%

    Paid Affiliates

    120,850; (8)%

    Sales Leaders

    26,915; (13)%

    "We delivered first quarter revenue in line with our expectations and made further progress in our strategic priorities while operating in a volatile environment," said Ryan Napierski, Nu Skin president and CEO. "As we move through 2026, we are focused on empowering our sales leaders to scale our intelligent wellness platform with our latest innovation, Prysm iO™, ahead of our full consumer rollout in the second half. We also continue to invest in laying the groundwork to expand our presence in emerging markets, including the formal launch of India anticipated in late 2026, while continuing to improve our operational discipline to return value to shareholders.

    "We are encouraged by early signs of improving paid affiliates and new sales leader development in several markets as our leaders begin integrating Prysm iO into their businesses and continue to build upon our leading anti-aging Tru Face® brand. We are focused on partnering with our sales force on leveraging the proprietary nutritional health biomarker tracking from Prysm iO to expand the channel as we prepare to drive customer subscriptions for our wellness products. While these initiatives will take time to develop, we remain confident that they will increase sales leader engagement and expand our global reach over time to drive the next phase of growth for Nu Skin."

    Q1 2026 Year-over-year Operating Results

    Revenue

    $320.6 million compared to $364.5 million

      • +1.1% FX impact or $3.9 million

    Gross Margin

    66.9% or 67.9% excluding certain charges compared to 67.8%

      • Nu Skin business was 76.9% compared to 76.7%

    Selling Expenses

    34.3% compared to 32.5%

      • Nu Skin business was 40.5% compared to 38.7%

    G&A Expenses

    30.7% or 29.9% excluding certain charges compared to 31.1% or 28.9% excluding certain charges

    Impairment Expenses

    $1.8 million impairment compared to $25.1 million impairment

    Operating Margin

    1.3% or 3.6% excluding certain charges compared to (2.7)% or 6.4% excluding impairment and other charges

    Interest Expense

    $4.3 million compared to $3.3 million

    Other Income (Expense)

    $2.8 million compared to $(28.4) million

     • Prior year reflects $28.1 million unrealized loss on investment

    Income Tax Rate

    29.4% compared to 20.1%

    EPS

    $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges 

    Stockholder Value

    Dividend Payments

    $2.9 million

    Stock Repurchases

    $5.0 million

      • $137.3 million remaining in authorization

    Q2 and Full-year 2026 Outlook

    Q2 2026 Revenue

    $330 to $360 million; (15)% to (7)%

      • Approximately 0% FX impact

    Q2 2026 EPS

    $0.15 to $0.25

    2026 Revenue

    $1.35 to $1.50 billion; (9)% to 1%

      • Approximately (1)% FX impact

    2026 EPS

    $0.70 to $1.10 or $0.80 to $1.20 excluding certain charges

    "In addition to delivering on revenue and adjusted earnings, we returned $8 million to shareholders in the form of dividends and share repurchases," said Chelsea Lantz, interim chief financial officer. "We were also able to refinance our debt, extending our liquidity as we invest in growth initiatives and navigate market volatility while executing on our strategy. We are maintaining our annual guidance for 2026 on an adjusted basis. For the second quarter, we project revenue between $330 million and $360 million, with earnings per share in the range of $0.15 to $0.25."

    Conference Call

    The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through May 21, 2026.

    About Nu Skin Enterprises Inc.

    Nu Skin Enterprises Inc. (NYSE:NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal care and wellness products. Rhyz is the strategic investment arm of Nu Skin Enterprises, formed in 2018 consisting of synergistic consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

    Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, growth, initiatives, plans, areas of focus, sales force and customers, shareholder value, Prysm launch and its timing and potential benefits to the business, and emerging market expansion and its timing; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "become," "continue," "project," "outlook," "guidance," "focus," "expand," "will," "would," "could," "may," "might," the negative of these words and other similar words.

    The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

    • any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
    • risk that direct selling laws and regulations in any of the company's markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
    • economic conditions and events globally;
    • the company's future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company's products imported into the company's markets, and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets;
    • competitive pressures in the company's markets;
    • risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;
    • adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
    • political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
    • uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
    • risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
    • uncertainties regarding the future financial performance of the businesses the company has acquired;
    • risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and
    • regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.

    The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

    Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period.

    Earnings per share, gross margin, general and administrative expenses, and operating margin, each excluding inventory write-off charges, impairment expense, the gain from the Mavely sale, unrealized investment loss, and/or other charges, also are non-GAAP financial measures.

    • Inventory write-off charges, impairment expense, and unrealized investment loss are not part of the ongoing operations of our underlying business; and
    • the gain from the Mavely sale, and the other charges incurred in connection with this sale and other corporate actions, are not part of our ongoing operations.

    The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items facilitates period-to-period comparisons of the company's performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin, income tax rate and revenue growth rate calculated under GAAP, below.

    The following table sets forth revenue for the three-month periods ended March 31, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):

     

    Three Months Ended

     

     

     

     

     

     

    Constant-

     

     

    March 31,

     

     

     

     

     

     

    Currency

     

     

     

    2026

     

     

     

    2025

     

     

     

    Change

     

     

     

    Change

     

    Nu Skin

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Americas

    $

    57,818

     

     

    $

    69,058

     

     

     

    (16.3

    )%

     

     

    (12.6

    )%

    Southeast Asia/Pacific

     

    45,474

     

     

     

    52,172

     

     

     

    (12.8

    )%

     

     

    (16.6

    )%

    Mainland China

     

    45,148

     

     

     

    47,775

     

     

     

    (5.5

    )%

     

     

    (10.0

    )%

    Japan

     

    39,739

     

     

     

    42,765

     

     

     

    (7.1

    )%

     

     

    (4.3

    )%

    Europe & Africa

     

    31,218

     

     

     

    33,021

     

     

     

    (5.5

    )%

     

     

    (14.8

    )%

    Hong Kong/Taiwan

     

    27,457

     

     

     

    28,447

     

     

     

    (3.5

    )%

     

     

    (5.9

    )%

    South Korea

     

    25,329

     

     

     

    32,515

     

     

     

    (22.1

    )%

     

     

    (21.4

    )%

    Nu Skin Other

     

    (234

    )

     

     

    529

     

     

     

    (144.2

    )%

     

     

    (144.4

    )%

    Total Nu Skin

     

    271,949

     

     

     

    306,282

     

     

     

    (11.2

    )%

     

     

    (12.5

    )%

    Rhyz

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Manufacturing

     

    44,925

     

     

     

    55,290

     

     

     

    (18.7

    )%

     

     

    (18.7

    )%

    Rhyz Other

     

    3,734

     

     

     

    2,918

     

     

     

    28.0

    %

     

     

    28.0

    %

    Total Rhyz

     

    48,659

     

     

     

    58,208

     

     

     

    (16.4

    )%

     

     

    (16.4

    )%

    Total

    $

    320,608

     

     

    $

    364,490

     

     

     

    (12.0

    )%

     

     

    (13.1

    )%

    The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended March 31, 2026 and 2025:

     

    Three Months Ended

     

     

     

     

     

    March 31,

     

     

     

     

     

     

    2026

     

     

     

    2025

     

     

     

    Change

     

    Customers

     

     

     

     

     

     

     

     

     

     

     

    Americas

     

    186,448

     

     

     

    227,514

     

     

     

    (18

    )%

    Southeast Asia/Pacific

     

    67,461

     

     

     

    74,584

     

     

     

    (10

    )%

    Mainland China

     

    104,721

     

     

     

    122,474

     

     

     

    (14

    )%

    Japan

     

    102,392

     

     

     

    107,742

     

     

     

    (5

    )%

    Europe & Africa

     

    115,343

     

     

     

    130,154

     

     

     

    (11

    )%

    Hong Kong/Taiwan

     

    35,899

     

     

     

    42,523

     

     

     

    (16

    )%

    South Korea

     

    57,271

     

     

     

    71,721

     

     

     

    (20

    )%

    Total Customers

     

    669,535

     

     

     

    776,712

     

     

     

    (14

    )%

    Paid Affiliates

     

     

     

     

     

     

     

     

     

     

     

    Americas

     

    27,039

     

     

     

    26,936

     

     

     

    0

    %

    Southeast Asia/Pacific

     

    18,163

     

     

     

    22,296

     

     

     

    (19

    )%

    Mainland China

     

    18,064

     

     

     

    19,859

     

     

     

    (9

    )%

    Japan

     

    19,224

     

     

     

    21,073

     

     

     

    (9

    )%

    Europe & Africa

     

    13,607

     

     

     

    15,184

     

     

     

    (10

    )%

    Hong Kong/Taiwan

     

    9,541

     

     

     

    9,622

     

     

     

    (1

    )%

    South Korea

     

    15,212

     

     

     

    16,548

     

     

     

    (8

    )%

    Total Paid Affiliates

     

    120,850

     

     

     

    131,518

     

     

     

    (8

    )%

    Sales Leaders

     

     

     

     

     

     

     

     

     

     

     

    Americas

     

    4,930

     

     

     

    6,174

     

     

     

    (20

    )%

    Southeast Asia/Pacific

     

    3,769

     

     

     

    4,542

     

     

     

    (17

    )%

    Mainland China

     

    5,489

     

     

     

    6,214

     

     

     

    (12

    )%

    Japan

     

    5,943

     

     

     

    6,210

     

     

     

    (4

    )%

    Europe & Africa

     

    2,314

     

     

     

    2,839

     

     

     

    (19

    )%

    Hong Kong/Taiwan

     

    2,123

     

     

     

    2,207

     

     

     

    (4

    )%

    South Korea

     

    2,347

     

     

     

    2,850

     

     

     

    (18

    )%

    Total Sales Leaders

     

    26,915

     

     

     

    31,036

     

     

     

    (13

    )%

    • "Customers" are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
    • "Paid Affiliates" are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as "Brand Affiliates" because their primary role is to promote our brand and products through their personal social networks.
    • "Sales Leaders" are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

     

    NU SKIN ENTERPRISES, INC.

    Consolidated Statements of Income (Unaudited)

    (U.S. dollars in thousands, except per share amounts)

     

     

    Three Months Ended

     

    March 31,

     

     

    2026

     

     

     

    2025

     

    Revenue

    $

    320,608

     

     

    $

    364,490

     

    Cost of sales

     

    106,145

     

     

     

    117,529

     

    Gross profit

     

    214,463

     

     

     

    246,961

     

     

     

     

     

     

     

     

     

    Operating expenses:

     

     

     

     

     

     

     

    Selling expenses

     

    110,054

     

     

     

    118,546

     

    General and administrative expenses

     

    98,544

     

     

     

    113,204

     

    Impairment expenses

     

    1,839

     

     

     

    25,114

     

    Total operating expenses

     

    210,437

     

     

     

    256,864

     

     

     

     

     

     

     

     

     

    Operating income (loss)

     

    4,026

     

     

     

    (9,903

    )

    Interest expense

     

    4,250

     

     

     

    3,283

     

    Gain on sale of business

     

    -

     

     

     

    176,162

     

    Other income (expense), net

     

    2,823

     

     

     

    (28,375

    )

     

     

     

     

     

     

     

     

    Income before provision for income taxes

     

    2,599

     

     

     

    134,601

     

    Provision for income taxes

     

    763

     

     

     

    27,086

     

     

     

     

     

     

     

     

     

    Net income

    $

    1,836

     

     

    $

    107,515

     

     

     

     

     

     

     

     

     

    Net income per share:

     

     

     

     

     

     

     

    Basic

    $

    0.04

     

     

    $

    2.16

     

    Diluted

    $

    0.04

     

     

    $

    2.14

     

     

     

     

     

     

     

     

     

    Weighted-average common shares outstanding (000s):

     

     

     

     

     

     

     

    Basic

     

    48,202

     

     

     

    49,764

     

    Diluted

     

    49,422

     

     

     

    50,328

     

     

    NU SKIN ENTERPRISES, INC.

    Consolidated Balance Sheets (Unaudited)

    (U.S. dollars in thousands)

     

     

     

    March 31,

     

     

     

    December 31,

     

     

     

    2026

     

     

     

    2025

     

    ASSETS

     

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

     

    Cash and cash equivalents

    $

    198,654

     

     

    $

    238,630

     

    Current investments

     

    1,751

     

     

     

    1,211

     

    Accounts receivable, net

     

    45,013

     

     

     

    39,544

     

    Inventories, net

     

    178,600

     

     

     

    178,643

     

    Prepaid expenses and other

     

    98,870

     

     

     

    89,670

     

    Total current assets

     

    522,888

     

     

     

    547,698

     

     

     

     

     

     

     

     

     

    Property and equipment, net

     

    381,610

     

     

     

    377,168

     

    Operating lease right-of-use assets

     

    70,350

     

     

     

    74,021

     

    Goodwill

     

    83,625

     

     

     

    83,625

     

    Other intangible assets, net

     

    39,290

     

     

     

    42,614

     

    Other assets

     

    279,035

     

     

     

    280,187

     

    Total assets

     

    1,376,798

     

     

     

    1,405,313

     

     

     

     

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

     

    Accounts payable

    $

    28,815

     

     

    $

    26,183

     

    Accrued expenses

     

    208,182

     

     

     

    217,551

     

    Current portion of long-term debt

     

    20,000

     

     

     

    20,000

     

    Total current liabilities

     

    256,997

     

     

     

    263,734

     

     

     

     

     

     

     

     

     

    Operating lease liabilities

     

    54,017

     

     

     

    57,640

     

    Long-term debt

     

    203,593

     

     

     

    204,187

     

    Other liabilities

     

    68,104

     

     

     

    74,512

     

    Total liabilities

     

    582,711

     

     

     

    600,073

     

     

     

     

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

     

     

     

    Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued

     

    91

     

     

     

    91

     

    Additional paid-in capital

     

    613,890

     

     

     

    635,994

     

    Treasury stock, at cost – 42.0 million and 42.4 million shares

     

    (1,560,799

    )

     

     

    (1,575,059

    )

    Accumulated other comprehensive loss

     

    (118,377

    )

     

     

    (116,105

    )

    Retained earnings

     

    1,859,282

     

     

     

    1,860,319

     

    Total stockholders' equity

     

    794,087

     

     

     

    805,240

     

    Total liabilities and stockholders' equity

    $

    1,376,798

     

     

    $

    1,405,313

     

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Gross Margin Excluding Impact of Inventory Write-off to GAAP Gross Margin

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

     

    Three months ended

    March 31,

     

     

     

    2026

     

     

    2025

     

     

    Gross profit

     

    $

    214,463

     

     

    $

    246,961

     

     

    Impact of inventory write-off

     

     

    3,116

     

     

     

    -

     

     

    Adjusted gross profit

     

    $

    217,579

     

     

    $

    246,961

     

     

     

     

     

     

     

     

     

     

    Gross margin

     

     

    66.9

    %

     

     

    67.8

    %

     

    Gross margin, excluding inventory write-off impact

     

     

    67.9

    %

     

     

    67.8

    %

     

     

     

     

     

     

     

     

     

    Revenue

     

    $

    320,608

     

     

    $

    364,490

     

     

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of General and Administrative Expenses Excluding Certain Charges to GAAP General and Administrative Expenses

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

     

    Three months ended

    March 31,

     

     

     

    2026

     

     

    2025

     

     

    General and administrative expenses

     

    $

    98,544

     

     

    $

    113,204

     

     

    Impact of other charges(1)

     

     

    (2,643

    )

     

     

    (7,966

    )

     

    Adjusted general and administrative expenses

     

    $

    95,901

     

     

    $

    105,238

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    General and administrative expenses as a percentage of revenue

     

     

    30.7

    %

     

     

    31.1

    %

     

    General and administrative expenses as a percentage of revenue, excluding certain charges

     

     

    29.9

    %

     

     

    28.9

    %

     

     

     

     

     

     

     

     

     

    Revenue

     

    $

    320,608

     

     

    $

    364,490

     

     

     

    (1) Other charges for the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges. Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units.

     

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

     

    Three months ended

    March 31,

     

     

     

    2026

     

     

    2025

     

     

    Operating income (loss)

     

    $

    4,026

     

     

    $

    (9,903

    )

     

    Impact of inventory write-off

     

     

    3,116

     

     

     

    -

     

     

    Impact of other charges(1)

     

     

    2,643

     

     

     

    7,966

     

     

    Impact of impairment

     

     

    1,839

     

     

     

    25,114

     

     

    Adjusted operating income

     

    $

    11,624

     

     

    $

    23,177

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating margin

     

     

    1.3

    %

     

     

    (2.7

    )%

     

    Operating margin, excluding certain charges

     

     

    3.6

    %

     

     

    6.4

    %

     

     

     

     

     

     

     

     

     

    Revenue

     

    $

    320,608

     

     

    $

    364,490

     

     

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share

    (in thousands, except for per share amounts)

     

     

     

     

     

     

     

     

     

     

    Three months ended

    March 31,

     

     

     

    2026

     

     

    2025

     

     

    Net income

     

    $

    1,836

     

     

    $

    107,515

     

     

    Impact of inventory write-off

     

     

     

     

     

    Inventory write-off

     

     

    3,116

     

     

     

    -

     

     

    Tax impact

     

     

    (1,065

    )

     

     

    -

     

     

    Impact of other charges:

     

     

     

     

     

     

     

    Other charges(1)

     

     

    2,643

     

     

     

    7,966

     

     

    Tax impact

     

     

    (903

    )

     

     

    (725

    )

     

    Impact of impairment expense:

     

     

     

     

     

     

     

    Impairment

     

     

    1,839

     

     

     

    25,114

     

     

    Tax impact

     

     

    (629

    )

     

     

    (5,433

    )

     

    Impact of Mavely sale

     

     

     

     

     

     

     

    Gain from Mavely sale

     

     

    -

     

     

     

    (176,162

    )

     

    Tax impact

     

     

    -

     

     

     

    31,104

     

     

    Impact of unrealized investment loss

     

     

     

     

     

     

     

    Unrealized investment loss

     

     

    -

     

     

     

    28,077

     

     

    Tax impact

     

     

    -

     

     

     

    (6,074

    )

     

    Adjusted net income

     

    $

    6,837

     

     

    $

    11,382

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Diluted earnings per share

     

    $

    0.04

     

     

    $

    2.14

     

     

    Diluted earnings per share, excluding restructuring impact

     

    $

    0.14

     

     

    $

    0.23

     

     

     

     

     

     

     

     

     

     

    Weighted-average common shares outstanding (000)

     

     

    49,422

     

     

     

    50,328

     

     

     

    NU SKIN ENTERPRISES, INC.

    Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share

     

     

     

     

     

     

     

     

     

     

    Year ended December 31,

     

     

     

    2026 -

    Low end

     

    2026 -

    High end

     

    Earnings Per Share

     

    $

    0.70

     

     

    $

    1.10

     

     

    Impact of inventory write-off

     

     

     

     

     

     

     

    Inventory write-off

     

     

    0.06

     

     

     

    0.06

     

     

    Tax impact

     

     

    (0.02

    )

     

     

    (0.02

    )

     

    Impact of other charges

     

     

     

     

     

     

     

    Other charges(1)

     

     

    0.05

     

     

     

    0.05

     

     

    Tax impact

     

     

    (0.02

    )

     

     

    (0.02

    )

     

    Impact impairment expense:

     

     

     

     

     

     

     

    Impairment

     

     

    0.04

     

     

     

    0.04

     

     

    Tax impact

     

     

    (0.01

    )

     

     

    (0.01

    )

     

    Adjusted EPS

     

    $

    0.80

     

     

    $

    1.20

     

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260507105655/en/

    Media: media@nuskin.com, (801) 345-6397

    Investors: investorrelations@nuskin.com, (801) 345-3577

    Get the next $NUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUS

    DatePrice TargetRatingAnalyst
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nu Skin downgraded by Jefferies with a new price target

    Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

    1/31/23 6:17:27 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

    DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $50.00 from $47.00 previously

    2/17/22 4:46:52 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Citigroup reiterated coverage on Nu Skin Enterprises with a new price target

    Citigroup reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $49.00 from $43.00 previously

    11/24/21 11:03:39 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    SEC Filings

    View All

    SEC Form S-8 filed by Nu Skin Enterprises Inc.

    S-8 - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    6/1/26 5:20:09 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    5/29/26 4:05:27 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    SEC Form SD filed by Nu Skin Enterprises Inc.

    SD - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    5/21/26 6:02:40 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Winett James M was granted 26,643 shares and sold $40,481 worth of shares (7,203 units at $5.62) as part of a pre-agreed trading plan, increasing direct ownership by 108% to 37,448 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    6/3/26 5:10:22 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Director Nathanson Laura was granted 26,643 shares, increasing direct ownership by 87% to 57,116 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    6/3/26 5:09:32 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Director Zorko Mark A was granted 26,643 shares, increasing direct ownership by 78% to 60,586 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    6/3/26 5:08:41 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Hatchett Steven Keith bought $52,855 worth of shares (5,500 units at $9.61), increasing direct ownership by 3% to 167,565 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    11/12/25 4:32:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    5/28/25 6:26:44 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nu Skin Enterprises Reports First Quarter Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue results within its guidance range. Executive Summary Q1 2026 vs. Prior-year Quarter Revenue $320.6 million; (12.0)%   • +1.1% FX impact or $3.9 million Earnings Per Share (EPS) $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges Customers 669,535; (14)% Paid Affiliates 120,850; (8)% Sales Leaders 26,915; (13)% "We delivered first quarter revenue in line with our expectations and made further progress in our strategic priorities while operating in a volatile environ

    5/7/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 10, 2026, to shareholders of record on May 29, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE:NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal car

    5/7/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Announce First Quarter 2026 Financial Results

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release first quarter 2026 results after the market closes on Thursday, May 7. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, May 21. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family

    4/13/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Leadership Updates

    Live Leadership Updates

    View All

    Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. "On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits," said Ryan Napierski, president and CEO. "We have a talented finance team who has led the ongoing work to improve our operational performance and strengthen our balance sheet over the past year. I am excited to work directly with Chels

    3/20/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Appoints Chayce Clark as COO

    Clark to expand on his responsibilities as chief legal officer to oversee company operational functions and revenue performance Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company's revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company's chief legal officer. "Chayce has been a valuable part of our executive team and an important voice in our efforts to become the world's leading intelligent beauty and wellness leadership opportunity platform," said Ryan Napierski, president and CEO. "

    3/9/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Appoints James Winett to Board of Directors

    Nu Skin Enterprises (US:NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. "Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience," said Steven J. Lund, executive chairman of the board. "He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience." Winett is a managing member of SIZE Adv

    6/2/25 12:19:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/12/24 4:47:17 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/6/24 10:20:59 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/4/24 10:21:31 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Financials

    Live finance-specific insights

    View All

    Nu Skin Enterprises Reports First Quarter Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue results within its guidance range. Executive Summary Q1 2026 vs. Prior-year Quarter Revenue $320.6 million; (12.0)%   • +1.1% FX impact or $3.9 million Earnings Per Share (EPS) $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges Customers 669,535; (14)% Paid Affiliates 120,850; (8)% Sales Leaders 26,915; (13)% "We delivered first quarter revenue in line with our expectations and made further progress in our strategic priorities while operating in a volatile environ

    5/7/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 10, 2026, to shareholders of record on May 29, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE:NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal car

    5/7/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Announce First Quarter 2026 Financial Results

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release first quarter 2026 results after the market closes on Thursday, May 7. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, May 21. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family

    4/13/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care